NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Down 8.9%
NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) traded down 8.9% during mid-day trading on Friday . The stock traded as low as $1.00 and last traded at $1.02, 533,474 shares traded hands during mid-day trading. A decline of 55% from the average session volume of 1,197,576 shares. The stock had previously closed at $1.12.
NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The firm had revenue of $1.49 million during the quarter.
In related news, major shareholder Pharma (Hong Kong) Co Pioneer sold 24,326 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $4.04, for a total transaction of $98,277.04. Following the transaction, the insider now owns 5,188,421 shares of the company’s stock, valued at $20,961,220.84. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Mijia Wu sold 63,492 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $2.53, for a total value of $160,634.76. The disclosure for this sale can be found here.
NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.
Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.